Date: 2014-09-19
Type of information: Nomination
Compound: member of the board of directors
Company: Oryzon Genomics (Spain)
Therapeutic area: Cancer - Oncology - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 19, 2014, Oryzon SA approved in its last General Shareholders meeting the incorporation of two US senior profiles to its Board of Directors. The company will improve the quality of its governance, transparency and progressive compliance of US regulations. Dr. Russell G Greig will chair the Compensations and Nominations Committee, Dr Greig has more than 30 years’ experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GSK, where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and SVP Worldwide Business Development. From 2008 to 2010, Dr Greig was also President of SR One, GSK’s Corporate Venture Group. He currently serves on a number of boards including public and private. He is the Chairman of AM Pharma, Venture Partner of Kurma Life Sciences, board member of Ablynx, Tigenix and of Edinburgh BioQuarter among others.
- Mr. Gregory Weaver will chair the Audit Committee, Mr. Weaver is an experienced biotech industry Chief Financial Officer, Director and Audit Committee Chairman, of public and VC funded companies ranging from start?up to over $1B market cap. In various executive management positions he has raised over $700M in new equity and debt with US and EU roadshows. Skilled in growing Wall Street support he has positioned multiple companies for sale or IPO. He has been CFO at Ilex Oncology, SIRNA and Celsion among others. He is currently CFO of Fibrocell Science, a public NASDAQ company and serves as NED with two other public US biotechnology companies where he is audit committee chairman.
Financial terms:
Latest news:
Is general: Yes
